Get the Stockscreener App
54.04
2.43%
1.28
Pre-market:
54.18
0.14
+0.26%
Grail Inc stock is traded at $54.04, with a volume of 892.60K.
It is up +2.43% in the last 24 hours and down -45.35% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$52.76
Open:
$53.08
24h Volume:
892.60K
Relative Volume:
0.75
Market Cap:
$2.18B
Revenue:
$117.67M
Net Income/Loss:
$-1.88B
P/E Ratio:
-0.8927
EPS:
-60.5369
Net Cash Flow:
$-621.36M
1W Performance:
+4.34%
1M Performance:
-45.35%
6M Performance:
+60.88%
1Y Performance:
+30.11%
1-Day Range:
$52.02
$56.15
1-Week Range:
$48.07
$58.28
52-Week Range:
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
54.04 | 2.13B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | TD Cowen | Hold |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
View All
Grail Inc Stock (GRAL) Latest News
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES - PR Newswire
Grail Insider Sold Shares Worth $1,881,417, According to a Recent SEC Filing - marketscreener.com
GRAIL (NASDAQ:GRAL) President Joshua Ofman Sells 17,002 Shares - MarketBeat
Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 37,504 Shares of Stock - MarketBeat
GRAL | GRAIL, Inc. Common Stock FinancialsIncome Statement - Quiver Quantitative
GRAIL (GRAL) president gets RSU grant, sells shares for taxes - Stock Titan
GRAIL (GRAL) CFO awarded 60,118 RSUs, sells shares to cover taxes - Stock Titan
GRAIL (GRAL) CEO sells 37,504 shares in automatic tax sell-to-cover - Stock Titan
GRAIL, Inc. Hits Day High with 12.18% Surge Amid Market Challenges - Markets Mojo
GRAIL, Inc. Hits Day Low of $41.50 Amid Price Pressure - Markets Mojo
GRAIL, Inc. (GRAL) Stock Analysis: Investor Outlook On A 67.21% Potential Upside - DirectorsTalk Interviews
GRAL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to AsiaSamsung Newsroom Global Media Library - samsung.com
GRAL: NHS-Galleri trial showed strong stage 4 cancer reduction and broad commercial momentum - TradingView
GRAIL (GRAL) Valuation Check As NHS Galleri Trial Data And Earnings Reset Growth Expectations - simplywall.st
Aaron Freidin to sell 23,076 GRAL shares under Rule 144 (NASDAQ: GRAL) - Stock Titan
GRAL (NASDAQ) insider sale: Robert Ragusa sells 40,000 shares; 74,873 RSUs vested - Stock Titan
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
GRAIL (NASDAQ:GRAL) Shares Gap DownHere's Why - MarketBeat
(GRAL) Risk Channels and Responsive Allocation - Stock Traders Daily
Archaeopteryx | The Holy Grail of Fossils at the Field Museum - Britannica
Kaplan Fox Alerts Investors of Grail, Inc. (GRAL) to an Investigation of Potential Securities Law Violations - NewMediaWire
GRAIL stock dips in premarket after a sharp bounce as Galleri trial fallout hangs over GRAL - TechStock²
Primecap Management Co. CA Sells 33,346 Shares of GRAIL, Inc. $GRAL - MarketBeat
Here’s What Analysts Are Saying About Grail Inc. (GRAL) - Yahoo Finance
After Grail’s Study Flop, What’s Left for Cancer Blood Screens - Barron's
Grail, Inc. (NASDAQ: GRAL) Shareholder InvestigationKaplan Fox Reviewing Potential Claims - The Globe and Mail
Why did my doctor push Grail’s dubious cancer test? - Endpoints News
WIM INVESTMENT MANAGEMENT Ltd Raises Stake in GRAIL, Inc. $GRAL - MarketBeat
Here's What Analysts Are Saying About Grail Inc. (GRAL) - Bitget
Galleri Cancer Detection Test Fails in Key Trial: Now What? - Medscape
Why Is GRAIL, Inc. (GRAL) Stock Up Today? - Meyka
Grail, Inc. (GRAL) Securities Investigation Announced by Kaplan Fox & Kilsheimer LLP - NewMediaWire
Why GRAIL (GRAL) Is Down 49.2% After NHS-Galleri Trial Misses Primary Endpoint And Mixed Data - simplywall.st
The elusive grail of blood tests that spot cancer early - Financial Times
Gossamer, Grail down by more than half after late-stage misses - biocentury.com
Grail Investor ALERT: Kaplan Fox is Investigating Grail, Inc. (NASDAQ: GRAL) for Potential Securities Law Violations - The National Law Review
Early cancer detection firm GRAIL joins TD Cowen health care conference - Stock Titan
Lost Money on GRAIL, Inc. (GRAL)? Possible FraudContact Levi & Korsinsky Today - TMX Newsfile
Here's Why Grail Stock Bounced Back 16% Today - Yahoo Finance
Silicon Valley company's stock nosedives by 50% after cancer test trial - SFGATE
GRAIL (NASDAQ:GRAL) Trading Up 15.8%Still a Buy? - MarketBeat
GRAL Stock Dips Amid Revenue Concerns and Market Trends - StocksToTrade
GRAL Stock Dips as Positive Developments Emerge - timothysykes.com
An Early Cancer Detection Test, Put To The Test - Seeking Alpha
GRAIL, Inc. (GRAL) Stock Analysis: Exploring a 104% Potential Upside Amidst Healthcare Innovations - DirectorsTalk Interviews
GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm (2026-02-24) - Seeking Alpha
Grail Stock Craters 47% After Cancer Drug Trial Fails To Meet Primary Endpoint - TIKR.com
GRAL ALERT: Kaplan Fox is Investigating Grail, Inc. (NASDAQ: GRAL) for Potential Securities Law Violations - NewMediaWire
Why Grail Shares Are Plummeting - Nasdaq
GRAIL (NASDAQ:GRAL) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):